Bioretec - Will the US market open?

Paavola timed his purchase quite well, hitting almost the same plank as the release of Inderes’ fresh analysis and the target price hike.

Paavola’s purchase is rather modest (10K euros) compared to many who have invested in the company here.

It smells faintly like they are trying to build at least some kind of buffer / cushion for the upcoming reverse split. For example, if they went with a 1:100 ratio, the current share price (0.022) would become 2.20 euros.

That is still quite close to the magic one-euro limit, after which it would be back in the “penny league” again.

This will likely need more good-sounding storytelling, including in the form of news.

Or then they have to split, say, 1:200.

But they probably can’t play around with the current “chump change” price for much longer.

(As a shareholder, I wouldn’t mind if it continued as a penny stock. After a while, all past twists and turns will be buried under other daily news, and from the perspective of many uninitiated investors, the share will start to look ridiculously cheap per unit and thus very attractive. A rise from, say, two cents to six cents is, after all, “only” four cents per share =))

2 Likes